Top Gap Ups and Downs on Wednesday: ADI, TJX, SCCO and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Express News | NYSE Order Imbalance 61878.0 Shares on Buy Side
Estimating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Qiagen's Updated Clinical Decision Support Platform Secures EU Certification
Qiagen (QIA.F) said Tuesday its updated clinical decision support platform secured certification in the European Union for technical documentation assessment and quality management system. The molecul
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret, Its Medical Device Software for Clinical Decision Support
Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight
QIAGEN Gets FDA Clearance for QIAstat-Dx Respiratory Panel Plus
QIAGEN (QGEN) to Enhance Forensics With New Partnership
QIAGEN N.V. QGEN recently entered into a cooperative research and development agreement (CRADA) with the Federal Bureau of Investigation (FBI).
Qiagen's (NYSE:QGEN) Investors Will Be Pleased With Their 15% Return Over the Last Five Years
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, wh
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel
Qiagen (QIA.F) on Monday said the US Food and Drug Administration authorized its QIAstat-Dx respiratory syndromic testing panel for clinical use. The molecular testing company's QIAstat-Dx Respiratory
Express News | NYSE Order Imbalance 92847.0 Shares on Buy Side
Express News | NYSE Order Imbalance 58834.0 Shares on Buy Side
QIAGEN Partners With FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law en
Express News | NYSE Order Imbalance 64100.0 Shares on Sell Side
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution for Oncology and Inherited Disease Applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances p
Express News | NYSE Order Imbalance 57864.0 Shares on Sell Side
Qiagen Is Maintained at Hold by Stifel
Qiagen Is Maintained at Hold by Stifel
Qiagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 6.31% Stifel $55 → $45 Maintains Hold 02/16/2024 20.48% Morgan Stanley $49.48 → $51 Upgrades Eq
Express News | Qiagen NV : Stifel Cuts Target Price to $45 From $55
Earnings Call Summary | Qiagen NV(QGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Qiagen reported Q1 2024 net sales of $462 million at constant exchange rates, an improvement